60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
July 19, 2024 08:29 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 09, 2024 06:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
June 27, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
June 11, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
May 30, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
May 20, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
May 15, 2024 13:45 ET
|
Sixty Degrees Pharmaceuticals
SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
May 08, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
May 02, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
April 03, 2024 07:58 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.